FDA issues warning over-the-counter diarrhea drug

(AP)—The Food and Drug Administration is warning consumers not to use an over-the-counter drug called Intestinomicina because the anti-diarrhea treatment contains a drug linked to life-threatening injuries.

The El Salvador-manufactured drug comes in pills and liquid forms and is sold as a treatment for at international grocery stores and specialty stores in the U.S.

Regulators say Intestinomicina contains the drug chloramphenicol, which can interfere with the production of red and . People with anemia and other low blood cell counts are at greater risk of injury or death from using the drug.

The FDA recalled all oral forms of chloramphenicol in July due to safety risks. The agency is asking consumers who purchased the product to stop taking it and consult a health care professional.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

US warns of drugs in Reumofan dietary supplements

Aug 21, 2012

(AP) — The U.S. Food and Drug Administration is warning consumers not to use Reumofan dietary supplements, after receiving reports of bleeding, stroke and death among Americans taking the Mexico-manufactured pills.

Perjeta approved for advanced breast cancer

Jun 11, 2012

(HealthDay) -- Perjeta (pertuzumab) has been approved by the U.S. Food and Drug Administration to treat people with HER2-positive late-stage breast cancer, the agency said in a news release.

Anemia drugs under scrutiny

Mar 13, 2008

U.S. drug regulators are contemplating further restrictions on the use of drugs to combat anemia in cancer patients.

Recommended for you

Have a cold? Don't ask your doctor for antibiotics

Nov 26, 2014

Antibiotic resistance is a major threat to public health. Resistance makes it harder for physicians to treat infections and can increase the chance patients will die from an infection. What is more, the treatment ...

Powdered measles vaccine found safe in early clinical trials

Nov 25, 2014

A measles vaccine made of fine dry powder and delivered with a puff of air triggered no adverse side effects in early human testing and it is likely effective, according to a paper to be published November 28 in the journal ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.